Government Doctors Are Not Allowed Private Practice: Health Ministry

NEW DELHI: As per Central Health Service (CHS) Rules, 2014, persons appointed to CHS shall not be allowed private practice of any kind whatsoever including any consultation and laboratory practice, according to the Ministry of Health. The ministry also informed the lower house today that doctors are entitled to a Non-Practicing Allowance (NPA) of 20% of Basic Pay subject to the condition that the Basic Pay plus NPA does not exceed Rs., 2,37,500/- after acceptance of the recommendations of the Seventh Central Pay Commission.

The Minister of State (Health and Family Welfare), Ashwini Kumar Choubey also stated in a written reply in the Lok Sabha here today that as and when any instance of private practice is brought to the notice of the Government, appropriate action is taken in the matter as per rules and procedure of the Government.

“As far as Central Government is concerned, as per Rule 13 of Central Health Service (CHS) Rules, 2014, persons appointed to CHS shall not be allowed private practice of any kind whatsoever including any consultation and laboratory practice,” the minister said.

“In lieu of private practice, doctors are entitled to a Non-Practicing Allowance (NPA) of 20% of Basic Pay subject to the condition that the Basic Pay plus NPA does not exceed Rs., 2,37,500/- after acceptance of the recommendations of the Seventh Central Pay Commission,” he added.

“Health being a State subject”, the minister also said, “no such information in respect of State Government Hospitals is maintained centrally”.

Related Posts

  • Pharma
  • May 30, 2025
  • 82 views
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

ICICI Securities has downgraded Aurobindo Pharma to Add (from Buy earlier) with a revised target price of Rs 1,330 (earlier Rs 1,445). The current market price of Aurobindo Pharma Ltd.…

  • Pharma
  • May 30, 2025
  • 53 views
AstraZeneca gets CDSCO nod for lung cancer drug

New Delhi:  AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

AstraZeneca gets CDSCO nod for lung cancer drug

AstraZeneca gets CDSCO nod for lung cancer drug

Anar Modi named CHO at Senores Pharma

Anar Modi named CHO at Senores Pharma

Natco Pharma Q4 Results: Profit Misses Estimates, Margin Contracts; FY26 Outlook Gloomy

Natco Pharma Q4 Results: Profit Misses Estimates, Margin Contracts; FY26 Outlook Gloomy